These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29118324)

  • 1. Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.
    Dai CH; Wang Y; Chen P; Jiang Q; Lan T; Li MY; Su JY; Wu Y; Li J
    Sci Rep; 2017 Nov; 7(1):15031. PubMed ID: 29118324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
    Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA
    Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
    Drápela S; Khirsariya P; van Weerden WM; Fedr R; Suchánková T; Búzová D; Červený J; Hampl A; Puhr M; Watson WR; Culig Z; Krejčí L; Paruch K; Souček K
    Mol Oncol; 2020 Oct; 14(10):2487-2503. PubMed ID: 32579780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
    Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
    J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma.
    Beumer JH; Fu KY; Anyang BN; Siegfried JM; Bakkenist CJ
    BMC Cancer; 2015 Oct; 15():649. PubMed ID: 26438152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells.
    Isono M; Okubo K; Asano T; Sato A
    Sci Rep; 2021 May; 11(1):10181. PubMed ID: 33986399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
    Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
    Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.
    Guzi TJ; Paruch K; Dwyer MP; Labroli M; Shanahan F; Davis N; Taricani L; Wiswell D; Seghezzi W; Penaflor E; Bhagwat B; Wang W; Gu D; Hsieh Y; Lee S; Liu M; Parry D
    Mol Cancer Ther; 2011 Apr; 10(4):591-602. PubMed ID: 21321066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe.
    Warren NJH; Eastman A
    J Biol Chem; 2019 Feb; 294(6):1763-1778. PubMed ID: 30573684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
    Montano R; Chung I; Garner KM; Parry D; Eastman A
    Mol Cancer Ther; 2012 Feb; 11(2):427-38. PubMed ID: 22203733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.
    Oo ZY; Proctor M; Stevenson AJ; Nazareth D; Fernando M; Daignault SM; Lanagan C; Walpole S; Bonazzi V; Škalamera D; Snell C; Haass NK; Larsen JE; Gabrielli B
    Mol Oncol; 2019 Jul; 13(7):1503-1518. PubMed ID: 31044505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer.
    Nieto-Jimenez C; Alcaraz-Sanabria A; Martinez-Canales S; Corrales-Sanchez V; Montero JC; Burgos M; Nuncia-Cantarero M; Pandiella A; Galan-Moya EM; Ocaña A
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.
    Sakurikar N; Thompson R; Montano R; Eastman A
    Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776.
    Engelke CG; Parsels LA; Qian Y; Zhang Q; Karnak D; Robertson JR; Tanska DM; Wei D; Davis MA; Parsels JD; Zhao L; Greenson JK; Lawrence TS; Maybaum J; Morgan MA
    Clin Cancer Res; 2013 Aug; 19(16):4412-21. PubMed ID: 23804422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
    Bryant C; Rawlinson R; Massey AJ
    BMC Cancer; 2014 Aug; 14():570. PubMed ID: 25104095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase.
    McNeely S; Conti C; Sheikh T; Patel H; Zabludoff S; Pommier Y; Schwartz G; Tse A
    Cell Cycle; 2010 Mar; 9(5):995-1004. PubMed ID: 20160494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chk1 inhibition induces a DNA damage bystander effect in cocultured tumour cells.
    Brooks T; Wayne J; Massey AJ
    DNA Repair (Amst); 2021 May; 101():103099. PubMed ID: 33740539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation.
    Liang M; Zhao T; Ma L; Guo Y
    Oncol Rep; 2018 Mar; 39(3):1322-1330. PubMed ID: 29286153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer.
    Grabauskiene S; Bergeron EJ; Chen G; Thomas DG; Giordano TJ; Beer DG; Morgan MA; Reddy RM
    J Surg Res; 2014 Mar; 187(1):6-13. PubMed ID: 24418519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.
    Boudny M; Zemanova J; Khirsariya P; Borsky M; Verner J; Cerna J; Oltova A; Seda V; Mraz M; Jaros J; Jaskova Z; Spunarova M; Brychtova Y; Soucek K; Drapela S; Kasparkova M; Mayer J; Paruch K; Trbusek M
    Haematologica; 2019 Dec; 104(12):2443-2455. PubMed ID: 30975914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.